drugset / Trial / NCT02460900

Optimizing Smoking Cessation for People With HIV/AIDS Who Smoke

NCT02460900

RandomizedFactorialQuadruple-blindTreatment

Summary

The single greatest health behavior change that could improve cardiovascular morbidity and associated mortality is to assist people living with HIV/AIDS who smoke to quit. The investigators will use a factorial design to evaluate the most promising behavioral and pharmacologic treatments aimed at achieving maximal efficacy for smoking cessation among people living with HIV/AIDS who smoke. Results of this study will provide crucial, real world evidence of the best way for healthcare providers to help smokers living with HIV/AIDS quit smoking.

Timeline

Start
2016-07
Primary completion
2021-04
Completion
2021-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Varenicline Small molecule